Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients

The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data

(2018) Irina Odnoletkova et al.   Orphanet Journal of Rare Diseases

Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases

(2017) Richard L Wasserman   Immunotherapy

Secondary antibody deficiency - causes and approach to diagnosis

(2016) S. Srivastava et al.   CLINICAL MEDICINE

Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability

(2016) Richard L Wasserman et al.   Immunotherapy

Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies

(2016) Mark R. Stein et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

(2016) Richard L. Wasserman et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”

(2016) B. Bienvenu et al.   Orphanet Journal of Rare Diseases

Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease

(2015) S. Jolles et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Facilitated subcutaneous immunoglobulin (fSCIg) therapy - practical considerations

(2015) M. Ponsford et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Primary vs. Secondary Antibody Deficiency: Clinical Features and Infection Outcomes of Immunoglobulin Replacement

(2014) Sai S. Duraisingham et al.   PLoS One

Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment

(2014) Teresa Espanol et al.   Patient Preference and Adherence

Use of Home-Based Subcutaneous Immunoglobulin Therapy in Elderly Patients with Primary Immunodeficiency Diseases

(2013) Robert M. Guthrie   POSTGRADUATE MEDICINE

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

(2012) Richard L. Wasserman et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Patient and parent preferences for immunoglobulin treatments: a conjoint analysis

(2012) Ateesha F. Mohamed et al.   JOURNAL OF MEDICAL ECONOMICS

Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy

(2011) S. V. Kaveri et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure

(2011) P. Bentley et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Safety and efficacy of Home-Based Subcutaneous Immunoglobulin G in Elderly Patients with Primary Immunodeficiency Diseases

(2011) Mark R. Stein et al.   POSTGRADUATE MEDICINE

Improved Quality of Life, Immunoglobulin G Levels, and Infection Rates in Patients with Primary Immunodeficiency Diseases during Self-Treatment with Subcutaneous Immunoglobulin G

(2011) Melvin Berger et al.   SOUTHERN MEDICAL JOURNAL

Subcutaneous immunoglobulin: opportunities and outlook

(2009) S. Misbah et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY